[Skip to Content]
[Skip to Content Landing]
Citations 0
January 21, 1998

Integrin β3 Blockade With Abciximab and Protection From Myocardial Ischemic Events—Reply

Author Affiliations

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(3):195-196. doi:10.1001/jama.279.3.193

In Reply.—Dr Conrad and associates cite an interesting mechanism by which integrin β3 blockade by abciximab may result in a protective effect from ischemic events. As is pointed out in the article by Topol et al,1 the benefit achieved with abciximab was unexpected at the longer-term follow-up. Perhaps a reduction in free radical formation by impairment of iron uptake into cells results in a reduction in oxidation of lipids in low-density lipoprotein, thereby stabilizing atherosclerotic plaque and preventing late atherosclerotic events. Whether the brief exposure to this agent, however, results in the improved long-term outcome based on this hypothesis is speculative. The improved longer-term outcome appears to be related primarily to a reduction in acute ischemic events, which is a platelet-mediated event.2 Interestingly, 2 subsequent studies, EPILOG3 and CAPTURE,4 which confirmed the reduction in early adverse events with abciximab, did not demonstrate the improved late outcome as seen in the EPIC trial.

First Page Preview View Large
First page PDF preview
First page PDF preview